Glaukos Co. (NYSE:GKOS) COO Joseph E. Gilliam Sells 2,059 Shares

Glaukos Co. (NYSE:GKOS) COO Joseph E. Gilliam sold 2,059 shares of the company’s stock in a transaction dated Thursday, May 2nd. The stock was sold at an average price of $105.52, for a total transaction of $217,265.68. Following the transaction, the chief operating officer now owns 101,845 shares in the company, valued at $10,746,684.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Glaukos Stock Performance

NYSE:GKOS opened at $104.95 on Tuesday. The company has a debt-to-equity ratio of 0.78, a current ratio of 5.38 and a quick ratio of 4.68. The firm has a market cap of $5.27 billion, a PE ratio of -36.44 and a beta of 1.08. The firm has a 50 day simple moving average of $93.59 and a 200-day simple moving average of $83.34. Glaukos Co. has a 1-year low of $54.38 and a 1-year high of $110.73.

Glaukos (NYSE:GKOS) last issued its quarterly earnings results on Wednesday, May 1st. The medical instruments supplier reported ($0.70) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.12). The business had revenue of $85.60 million during the quarter, compared to analyst estimates of $79.60 million. Glaukos had a negative net margin of 43.15% and a negative return on equity of 24.69%. The company’s revenue was up 15.8% on a year-over-year basis. During the same quarter last year, the firm posted ($0.59) earnings per share. On average, equities analysts expect that Glaukos Co. will post -2.2 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on GKOS shares. Mizuho upped their price target on Glaukos from $85.00 to $100.00 and gave the stock a “neutral” rating in a report on Thursday, April 11th. Needham & Company LLC upped their target price on Glaukos from $108.00 to $113.00 and gave the company a “buy” rating in a report on Thursday, May 2nd. Wells Fargo & Company lifted their price target on Glaukos from $103.00 to $110.00 and gave the stock an “overweight” rating in a research note on Thursday, May 2nd. BTIG Research increased their price objective on shares of Glaukos from $107.00 to $112.00 and gave the company a “buy” rating in a research note on Thursday, May 2nd. Finally, Stifel Nicolaus restated a “buy” rating and set a $110.00 target price on shares of Glaukos in a report on Wednesday, April 3rd. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $108.64.

Institutional Trading of Glaukos

A number of hedge funds have recently added to or reduced their stakes in GKOS. Duality Advisers LP purchased a new position in shares of Glaukos during the 1st quarter worth about $3,476,000. Texas Permanent School Fund Corp raised its stake in Glaukos by 1.5% during the first quarter. Texas Permanent School Fund Corp now owns 42,709 shares of the medical instruments supplier’s stock worth $4,027,000 after purchasing an additional 622 shares during the period. Allspring Global Investments Holdings LLC boosted its holdings in shares of Glaukos by 127.5% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 166,054 shares of the medical instruments supplier’s stock valued at $15,657,000 after purchasing an additional 93,076 shares during the last quarter. Valeo Financial Advisors LLC grew its stake in shares of Glaukos by 1.7% during the 1st quarter. Valeo Financial Advisors LLC now owns 8,932 shares of the medical instruments supplier’s stock valued at $902,000 after buying an additional 150 shares during the period. Finally, Caldwell Sutter Capital Inc. increased its holdings in shares of Glaukos by 5,860.0% during the 1st quarter. Caldwell Sutter Capital Inc. now owns 1,490 shares of the medical instruments supplier’s stock worth $140,000 after buying an additional 1,465 shares during the last quarter. 99.04% of the stock is owned by institutional investors and hedge funds.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.